Sleep improving agent

Proline-3-alkyl diketopiperazines induce HSP expression to enhance sleep quality, reduce stress, and regulate autonomic nerves, addressing the limitations of current agents in these areas.

JP2024161450APending Publication Date: 2024-11-19AMINO UP CO LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024134789
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-05-26
Filing Date
2024-08-13
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current technologies lack effective agents that can induce heat shock protein (HSP) expression to improve sleep quality, alleviate stress, and regulate autonomic nerves.

Method used

The use of proline-3-alkyl diketopiperazines or their salts, represented by a specific general formula, to induce HSP expression, thereby enhancing sleep quality, reducing stress, and regulating autonomic nerves.

Benefits of technology

The compounds effectively induce HSP expression, improving sleep quality, reducing stress, and balancing autonomic nerve activity, thereby preventing or ameliorating related diseases and symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161450000015
    Figure 2024161450000015
  • Figure 2024161450000016
    Figure 2024161450000016
  • Figure 2024161450000017
    Figure 2024161450000017
Patent Text Reader

Abstract

To provide a heat shock protein expression-inducing agent, comprising an active ingredient having an excellent heat shock protein expression inducing activity, as well as a sleep improving agent, an anti-stress agent and an autonomic nerve-adjusting agent.SOLUTION: The present invention provides a heat shock protein expression-inducing agent, comprising a compound represented by formula (I) or a salt thereof [where R is a lower alkyl, a phenyl, or a hydroxyphenyl].SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This patent application claims priority to Japanese Patent Application No. 2016-105477, the entire contents of which are incorporated herein by reference. The present invention relates to a heat shock protein expression inducer, a sleep improving agent, an anti-stress agent and an autonomic nerve regulator. [Background technology]

[0002] Living organisms have various defense mechanisms to adapt to their growing environment. For example, when the growing temperature rises by 5 to 10 degrees Celsius, the three-dimensional structure of cellular proteins begins to change due to thermal denaturation, but a mechanism is known to repair this change using a group of proteins called "chaperones." Heat shock proteins (HSPs) are known as representative proteins that perform the chaperone function. Currently, more than a dozen types of HSPs have been reported in mammals, and they are classified into the HSP20 family, HSP40 family, HSP70 family, HSP90 family, etc. according to their molecular weight.

[0003] HSPs are also called stress proteins, and their expression in vivo is enhanced in response to environmental stress, pathological stress, psychological stress, etc. HSPs expressed in vivo undergo various stresses and undergo partial changes in their higher-order structure, and they specifically bind to proteins that are losing their original physiological functions, and use the energy generated during ATP hydrolysis to restore the higher-order structure of the binding partner protein to its original structure, thereby playing a role in restoring physiological functions. In this way, HSPs contribute to biological defense and maintaining homeostasis in the body, and if HSP expression can be induced in the body, it will be effective in preventing or ameliorating various diseases and symptoms caused by abnormalities in the higher-order structure of proteins, or various diseases and symptoms associated with HSPs.

[0004] Among HSPs, HSP70 in particular has been actively studied, and in recent years, the relationship between HSP70 and sleep (Non-Patent Documents 1 and 2) and stress (Non-Patent Documents 3 and 4) has become clear. It is also known that there is a close relationship between stress and autonomic nervous system disorders. Therefore, it is believed that the chaperone function of HSP70 contributes to recovery from damage caused by lack of sleep, daily stress, autonomic nervous system disorders, etc. For this reason, research is being conducted into the application of HSP70 expression inducers to medicines, quasi-drugs, and the like, and one such substance that has been reported is zerumbone (Patent Document 1). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] WO2012 / 043808 [Non-patent literature]

[0006] [Non-Patent Document 1] Doklady Biological Sciences, 2013, Vol.449, pp. 89-92 [Non-Patent Document 2] Doklady Biological Sciences, 2015, Vol.461, pp. 76-79 [Non-Patent Document 3] Exp. Ther. Med. 2012, Oct;4(4), 627-632 [Non-Patent Document 4] J. Biol. Chem. 2000, Vol.275, No.27, 20822-20828 Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide an HSP expression inducer, a sleep improver, an anti-stress agent, an autonomic nerve regulator, and the like, which contains an active ingredient having excellent HSP expression-inducing activity. [Means for solving the problem]

[0008] As a result of intensive research aimed at solving the above problems, the present inventors have found that a proline-containing 3-alkyldiketopiperazine represented by the following general formula (I) or a salt thereof has an excellent HSP expression-inducing effect, and based on this, exhibits sleep-improving effects, anti-stress effects, autonomic nerve regulating effects, etc., and have thus completed the present invention. That is, the present invention includes the following aspects. [1] Formula (I):

[0009] [ka] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof. [2] The heat shock protein expression inducer according to [1] above, wherein R is isopropyl, phenyl, or hydroxyphenyl. [3] The heat shock protein expression inducer according to [1] above, wherein R is isopropyl. [4] The heat shock protein expression inducer according to any one of the above [1] to [3], which is in the form of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition. [5] Formula (I):

[0010] [ka] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof. [6] The sleep improving agent according to the above [5], wherein R is isopropyl, phenyl, or hydroxyphenyl. [7] The sleep improver according to the above [5], wherein R is isopropyl. [8] The sleep-improving agent according to any one of the above [5] to [7], which is in the form of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition. [9] Formula (I):

[0011] [ka] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof.

[10] The autonomic nervous regulator described in [9] above, wherein R is isopropyl, phenyl, or hydroxyphenyl.

[11] The autonomic nervous system regulator described in [9] above, wherein R is isopropyl.

[12] The autonomic nervous regulator according to any one of the above [9] to

[11] , which is in the form of a pharmaceutical composition, a quasi-drug composition or a food and beverage composition.

[13] Formula (I):

[0012] [ka] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof.

[14] The anti-stress agent according to the above

[13] , wherein R is isopropyl, phenyl, or hydroxyphenyl.

[15] The anti-stress agent according to the above

[13] , wherein R is isopropyl.

[16] The anti-stress agent according to any one of the above

[13] to

[15] , which is in the form of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition. Effect of the Invention

[0013] According to the present invention, it is possible to provide an HSP expression inducer, a sleep-improving agent, an anti-stress agent, an autonomic nerve regulator, and the like, which have one or more of the following functional effects. (1) Induce expression of HSP70. (2) Improve the quality of sleep. Specifically, improve one or more of the following: quality of sleep, sleep-wake rhythm, feeling of deep sleep, feeling of waking up, feeling of fatigue upon waking, daytime sleepiness, work efficiency, and depressed mood caused by not being satisfied with sleep. (3) Anti-stress effect. (4) Autonomic nervous system regulating effect. (5) Prevention or amelioration of various diseases and symptoms caused by abnormalities in the higher-order structure of proteins, or various diseases and symptoms associated with HSP. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 shows the amount of HSP70 mRNA expression caused by proline-containing 3-alkyldiketopiperazine (compound 1). [Diagram 2] FIG. 2 is a graph showing the amount of HSP70 mRNA expression caused by proline-containing 3-alkyldiketopiperazine (compound 2). [Diagram 3] FIG. 3 is a graph showing the amount of HSP70 mRNA expression caused by proline-containing 3-alkyldiketopiperazine (compound 3). [Figure 4] FIG. 4 shows changes in the amount of light period activity in rats after phase advance. [Diagram 5] FIG. 5 shows the amount of activity of rats during the light period (12 hours) on the first day after the phase advance. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] The HSP expression inducer of the present invention contains, as an active ingredient, a compound represented by the following general formula (I):

[0016] [ka] wherein R is lower alkyl, phenyl, or hydroxyphenyl. The present invention includes a proline-containing 3-alkyl diketopiperazine represented by the following formula:

[0017] The "lower alkyl" in the above formula (I) means a linear or branched alkyl group having 1 to 6 carbon atoms, and specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, isohexyl, etc. Preferably, a linear or branched alkyl group having 1 to 4 carbon atoms, such as isopropyl, is used.

[0018] R in the above formula (I) is lower alkyl, phenyl, or hydroxyphenyl, preferably isopropyl, phenyl, or hydroxyphenyl, and particularly preferably isopropyl.

[0019] Among the proline-containing 3-alkyldiketopiperazines of the above formula (I), the following compounds 1 to 3 (particularly compound 1) are particularly preferred.

[0020] (Compound 1) Name: (3S,8aS)-3-isobutylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione Abbreviation: Cyclo(L-Leu-L-Pro) [ka]

[0021] (Compound 2) Name: (3S,8aS)-3-benzylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione Abbreviation: Cyclo(L-Phe-L-Pro) [ka]

[0022] (Compound 3) Name: (3S,8aS)-3-(4-hydroxybenzyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Abbreviation: Cyclo(L-Tyr-L-Pro) [ka]

[0023] The salts of the above-mentioned proline-containing 3-alkyldiketopiperazines include those acceptable for use in pharmaceuticals and food and beverages, such as salts with inorganic bases, salts with organic bases, and salts with basic amino acids. Suitable examples of salts with inorganic bases include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts, and the like. Suitable examples of salts with organic bases include salts with alkylamines (trimethylamine, triethylamine, etc.), heterocyclic amines (pyridine, picoline, etc.), alkanolamines (ethanolamine, diethanolamine, triethanolamine, etc.), dicyclohexylamine, N,N'-dibenzylethylenediamine, etc. Suitable examples of salts with basic amino acids include salts with arginine, lysine, ornithine, and the like. Of these salts, the alkali metal salts or alkaline earth metal salts are preferred, with the sodium salt being particularly preferred.

[0024] The proline-containing 3-alkyldiketopiperazine or a salt thereof used in the present invention can be prepared according to a method known in the art, for example, a chemical synthesis method, an enzymatic method, a microbial fermentation method, etc. Specifically, it can be synthesized by subjecting a linear peptide to a dehydration / cyclization reaction, for example, according to the method described in JP-A-2003-252896 and J. Peptide Sci., 10, 737-737 (2004). Moreover, the above compounds 1 to 3 are known compounds and can be obtained, for example, from BACHEM.

[0025] In the present invention, the above-mentioned proline-containing 3-alkyl diketopiperazine or its salt may be used alone or in combination of two or more as an active ingredient. For example, among the above-mentioned compounds 1 to 3, one may be used alone, or two or three may be used. For example, when two of the above compounds 1 to 3 are used, the ratio of their use is not particularly limited, but for example, when two compounds, 1 and 2, are used, compound 1:compound 2=10-0.5:3-0.1, preferably 6-1:2-0.5; when two compounds, 1 and 3, are used, compound 1:compound 3=10-0.5:5-0.5, preferably 6-1:4-0.7; and when two compounds, 2 and 3, are used, compound 2:compound 3=3-0.1:5-0.5, preferably 0.5:4-0.7. Furthermore, for example, when all (three) types of the above compounds 1 to 3 are used, the ratio of their use is not particularly limited, but is, for example, compound 1: compound 2: compound 3 = 10-0.5: 3-0.1: 5-0.5, and preferably 6-1: 2-0.5: 4-0.7.

[0026] The above-mentioned proline-containing 3-alkyldiketopiperazine or its salt has an excellent HSP expression-inducing effect, and therefore the HSP expression inducer of the present invention containing the compound as an active ingredient is effective in preventing or improving various diseases and symptoms caused by abnormalities in the higher-order structure of proteins, or various diseases and symptoms associated with HSPs. In the present invention, the HSPs to be induced in expression include HSP20 family proteins such as HSP20, HSP27, and HSP28, HSP40 family proteins such as HSP40 and HSP47, HSP70 family proteins such as HSP70, HSP72, and HSP73, and HSP90 family proteins such as HSP90a and HSP90b. HSP70 family proteins are preferred, and HSP70 is more preferred. In the present invention, the induction of HSP expression includes in vivo and in vitro expression, but is preferably in vivo expression. In addition, the in vivo site where HSP expression is induced is preferably the brain.

[0027] The above-mentioned proline-containing 3-alkyldiketopiperazine or a salt thereof exhibits excellent sleep-improving effects, anti-stress effects, autonomic nerve regulating effects, etc. based on the HSP expression-inducing effect. Therefore, the present invention also provides sleep-improving agents, anti-stress agents, autonomic nerve regulators and the like, which contain the above-mentioned proline-containing 3-alkyldiketopiperazine or a salt thereof as an active ingredient.

[0028] In the present invention, "improving sleep" refers to observing one or more improving effects such as sleep quality, sleep-wake rhythm, feeling of deep sleep, feeling of waking up, feeling of fatigue upon waking, daytime sleepiness, work efficiency, and depressed mood resulting from dissatisfied sleep. Improving sleep quality means obtaining good quality sleep by shortening the sleep onset latency, decreasing the number and duration of awakenings during the night, smoothly transitioning to slow-wave sleep, which is considered deep sleep, and increasing the time spent in deep sleep. Improving sleep-wake rhythm means correcting the deviation in sleep-wake rhythm and regulating the sleep-wake rhythm. Deviation in sleep-wake rhythm also includes social jet lag, which occurs when social time does not match the biological clock due to major changes in the nighttime light environment or work environment. In other words, it also means deviation in sleep-wake rhythm between weekdays, when there are social constraints such as work, and weekends, when there are no constraints, or disruption of the circadian rhythm of the body due to irregular sleep cycles. By improving the quality of sleep and / or sleep-wake rhythm, you can have a good night's sleep and wake up feeling refreshed. Furthermore, you will not feel sleepy during the day or tired when you wake up, and your work efficiency will improve. It will also reduce the depression caused by not getting a good night's sleep or having a misaligned sleep-wake rhythm. An ameliorative effect refers to the improvement of a symptom or condition, the prevention or delay of the worsening of a symptom or condition, or the reversal, prevention or delay of the progression of a symptom.

[0029] In the present invention, the "anti-stress effect" refers to preventing fatigue caused by stress in mammals, particularly humans, or preventing fatigue caused by brain stress. Here, fatigue refers to a temporary phenomenon of decreased physical and mental performance observed when physical or mental load is continuously applied. Decreased performance refers to a qualitative or quantitative decrease in physical and mental ability.

[0030] In the present invention, the "autonomic nervous system regulating effect" refers to improving the disturbance of the balance between sympathetic and parasympathetic nerves (balance of autonomic nerves) caused by excessive stress load, the decrease in autonomic nerve activity, etc. For example, since the function of the digestive tract is mainly controlled by the parasympathetic nerves, if the tension of the sympathetic nerves continues due to stress load, the function of the digestive tract is suppressed, and gastrointestinal disorders such as loss of appetite and constipation are caused. In addition, if the parasympathetic nerves do not function well due to stress load and the activity of the sympathetic nerves continues to be enhanced, it is thought that insomnia will be caused. As mentioned above, while there is a close relationship between stress and the autonomic nerves, there are also autonomic nerve disorders that are not caused by stress load. In addition, stress load does not necessarily cause autonomic nerve disorders, and may induce other physical symptoms.

[0031] In the present invention, the above-mentioned proline-containing 3-alkyldiketopiperazine or its salt can be used as it is as an HSP expression inducer, sleep improver, anti-stress agent, autonomic nerve regulator, etc. (hereinafter referred to as "HSP expression inducer, etc."). In addition, it can be used in combination with a carrier that can be added to medicines and quasi-drugs, or a food additive, within a range that does not affect the intended action and effect.

[0032] In addition, in the present invention, the above-mentioned proline-containing 3-alkyldiketopiperazine or its salt can be added to various pharmaceuticals, quasi-drugs, cosmetics, and food and beverage products as an HSP expression inducer, etc., and can be used in the form of a pharmaceutical composition, a quasi-drug composition, a food and beverage composition, etc. The above-mentioned medicines, quasi-drugs, and food and drink products are not particularly limited as long as they are commonly used, and examples thereof include tablets, granules, capsules, powders, tubular tablets, confectioneries (cookies, biscuits, chocolate confectioneries, chips, cakes, gums, candies, gummies, buns, yokan, puddings, jellies, yogurt, ice cream, sherbets, etc.), breads, noodles, rice, cereal foods, beverages (liquids, soft drinks, carbonated drinks, nutritional drinks, powdered drinks, fruit drinks, milk drinks, jelly drinks, etc.), soups (powdered, freeze-dried), miso soup (powdered, freeze-dried), etc. In addition, the food and drink products include functional foods, foods for specified health uses, health foods, nutritional supplements (supplements), medical foods, etc.

[0033] The subjects of the HSP expression inducer of the present invention are not particularly limited, but may include subjects who have subjective dissatisfaction with sleep, such as shallow sleep, not enough sleep when waking up, difficulty falling asleep, lack of deep sleep (not deep sleep), poor dreams, and fatigue, subjects who have no subjective dissatisfaction with sleep but feel fatigued and want to improve the quality of their sleep, subjects who feel autonomic nerve disorder, and subjects who feel stress in daily life. Also, subjects without any particular problems may take it daily for the purpose of maintaining good sleep, preventing sleep disorders, improving sleep quality, regulating autonomic nerves, and anti-stress effects. In addition, the subject of the present invention is particularly humans, but the present invention is also applicable to mammals other than humans (e.g., mice, rats, hamsters, monkeys, cows, horses, pigs, sheep, goats, dogs, cats, guinea pigs, rabbits, etc.).

[0034] In the HSP expression inducers and the like of the present invention, the daily administration (intake) amount of the proline-containing 3-alkyldiketopiperazine or its salt is not particularly limited and may be appropriately set depending on the purpose of administration (target disease or symptom), the administration form, and the sex, weight, age, and the like of the subject. For example, in the case of an adult human, the daily administration amount is usually 0.1 μg to 1.7 g, preferably 1 μg to 1.5 g, and more preferably 5 μg to 1.3 g, calculated as proline-containing 3-alkyldiketopiperazine. The daily dose of the above-mentioned compound 1 for an adult human is usually 0.5 μg to 500 mg, preferably 1 μg to 450 mg, and more preferably 10 μg to 400 mg. The daily dose of the above compound 2 for an adult human is usually 0.1 μg to 400 mg, preferably 2 μg to 350 mg, and more preferably 5 μg to 300 mg. The daily dose of the above compound 3 for an adult human is usually 0.1 μg to 800 mg, preferably 2 μg to 700 mg, and more preferably 5 μg to 600 mg.

[0035] The timing of administration of the HSP expression inducer of the present invention is not particularly limited, but it is preferable to administer (ingest) it once a day before going to bed.

[0036] The present invention also provides the above-mentioned proline-containing 3-alkyldiketopiperazine or a salt thereof for use as an HSP expression inducer, a sleep-improving agent, an anti-stress agent, an autonomic nerve regulator, or the like. The present invention further provides use of the above-mentioned proline-containing 3-alkyldiketopiperazine or a salt thereof for producing an HSP expression inducer, a sleep-improving agent, an anti-stress agent, an autonomic nerve regulator, or the like. In addition, the present invention provides a method for inducing HSP expression, a method for improving sleep, an anti-stress method, a method for regulating autonomic nerves, and the like, which comprise administering the above-mentioned proline-containing 3-alkyldiketopiperazine or a salt thereof to a subject. In these embodiments, the definitions of terms, the proline-containing 3-alkyldiketopiperazine or a salt thereof, the form of use, subjects, dosage, administration timing, amount in each agent, and the like are the same as those described above. EXAMPLES

[0037] Representative examples are given below, but the present invention is not limited thereto. Unless otherwise specified, "%" indicates "% by weight."

[0038] (Example 1) Evaluation of HSP70 mRNA expression induction effect The HSP70 expression-inducing action of Compounds 1 to 3 was evaluated by measuring the expression level of HSP70 mRNA. Leukemia cell line cells (HL-60 cells) were suspended in RPMI1640 medium supplemented with 10% fetal bovine serum and seeded in a 1.5 mL tube (45,000 cells / 0.9 mL). 0.1 mL of the sample prepared in 1% DMSO solution was added and left at 37°C for 4 hours. 0.1 mL of 1% DMSO solution was added to the control. After 4 hours of culture, the cells were centrifuged in a small refrigerated centrifuge (1,000g x 5 minutes) to precipitate the HL-60 cells. After removing the supernatant, the cells were dissolved in 0.25 mL of Trizol (Thermo Fisher Scientific), and total RNA was extracted according to the protocol. After dissolving in RNase-free water, the RNA concentration (wavelength 260 nm) was measured using a microspectrophotometer NanoDrop2000 / 2000c (Thermo Fisher Scientific). The RNA solution was diluted to a concentration of 50ng / mL with RNase-free water and incubated with ReverTra Ace. (R) cDNA was synthesized using qPCR RT Kit (TOYOBO). The reaction solution after reverse transcription (10 μl) was diluted with RNase-free water to 100 μl and used as a template for PCR. The beta 2 microglobulin gene was used as an internal standard gene to correct the expression of the HSP70 gene. The primer sequences of each gene used in the PCR reaction are as follows. HSP70 forward primer: GCATTTCCTAGTATTTCTGTTTGT (SEQ ID NO: 1) HSP70 reverse primer: AATAGTCGTAAGATGGCAGTATA (SEQ ID NO: 2) beta 2 microglobulin forward primer: TAGCTGTGCTCGCGCTACT (sequence number 3) beta 2 microglobulin reverse primer: AGTGGGGGTGAATTCAGTGT (SEQ ID NO: 4)

[0039] A CFX Connect real-time PCR analysis system (Bio-Rad) was used for expression analysis. 10 μL of PCR reaction solution was incubated at 95°C for 3 minutes (initial denaturation), followed by 55 cycles of denaturation at 95°C for 10 seconds, annealing at 57.8°C for 30 seconds, and extension. Finally, melting curves were measured at 0.2°C intervals in the range from 65°C to 95°C. Expression levels of HSP70 genes and internal control genes were analyzed using Bio-Rad CFX Manager 3.1.

[0040] The HSP70 mRNA expression induction ability of compounds 1, 2, and 3 is shown in Figures 1 to 3 as a percentage of the control. From these results, it was revealed that all samples enhanced the mRNA expression of the HSP70 gene compared to the control. In addition, when the concentration dependency of the HSP70 mRNA expression induction ability of each active ingredient was examined, the concentrations that increased the HSP70 mRNA expression induction ability to 150% compared to the control were 0.083 mg / ml for compound 1, 0.045 mg / ml for compound 2, and 0.101 mg / ml for compound 3.

[0041] Example 2 Seven-week-old male Wistar rats were administered a small activity monitor (NanoTag (R) A 1-week recovery period was then followed by stratified randomization of the animals into four groups (Control group, Compound A-1 group, Compound A-2 group, Compound A-3 group; n=17 each) shown in Table 1, and the animals were fed the test feed. On the 15th day after the start of feeding, the light-dark cycle was advanced by 8 hours, and the test feed was continued for two weeks. The light-dark cycle in the rearing environment was set to a 12-hour cycle except for the day of phase advance, and the illuminance of the light period was set to approximately 200lx (185-230lx). In this model of mild sleep disorder caused by phase advance, the effect of feeding the test feed on the amount of activity during the light period after the phase advance was examined. The test was a two-sided test, with a significance level of 5% and a trend difference of 10% on both sides. SAS software release 9.3 (SAS Institute Japan, Ltd.) was used for the analysis. [Table 1]

[0042] [result] Figure 4 shows the change in light-phase activity of rats after the phase advance. The horizontal axis shows the number of days since the phase advance, and the vertical axis shows the light-phase (12 hours) activity, with the average value ± standard error shown for the activity. For the pre3 days, the average light-phase activity for the 3-day pre-administration period is shown. The shape of the graph indicates that activity increases after the phase advance, and returns to the level before the phase advance over time.

[0043] In order to confirm the effect of Compound A on the amount of activity during the light period on the first and second days, where the increase in activity was particularly significant from Figure 4, a Dunnett test with Mixed model for repeated measures method was performed. The Compound A-3 group showed a tendency to suppress the amount of activity more than the Control group (P = 0.0978), and the Compound A-2 group suppressed the amount of activity more significantly than the Control group (P = 0.0481). These results suggest that Compound A suppresses sleep disorders caused by phase advance during the light period from the first to the second day.

[0044] Figure 5 shows the activity of rats during the light period (12 hours) on the first day after the phase advance. The horizontal axis represents each group, and the vertical axis represents the activity during the light period (12 hours). The activity is shown as the mean value ± standard error. A comparison between groups using the Dunnett test showed that the Compound A-3 group tended to suppress activity compared to the control group (P=0.0536), and the Compound A-2 group significantly suppressed activity compared to the control group (P=0.016). These results suggest that Compound A suppresses the deterioration of sleep due to phase advance during the light period (12 hours) on the first day.

[0045] As described above, both Fig. 4 and Fig. 5 show significant differences in the early light period in which activity is most likely to be disturbed after the phase advance, suggesting that compound A improves the quality of sleep.

[0046] (Example 3) The method described in Wada T. et al., Brain Res Bull. 2006; 69: 388-92. EEG electrodes are implanted into the brains of 8-week-old male Wistar rats, and a one-week recovery period is allowed after surgery. After that, the rats are allowed to habituate to the stimulation with the brush (sleep deprivation stimulation) for 2-3 days. On the test day, while monitoring the EEG data, if non-REM sleep is detected, the rats are stimulated with the brush to disrupt non-REM sleep. The effect of the test drug on the disruption of non-REM sleep is examined.

[0047] (Example 4) The method described in Miyazaki K. et al., PLoS One. 2013; 8: e55452. Male C3H-HeN mice aged 8 to 15 weeks are raised in cages with a running cage on paper flooring, but on the first day of the test, they are moved from a room temperature condition with 1.5 cm of water immersion to a condition where they are stressed. Under this condition, the mice live on the running cage to avoid water immersion. The activity of the mice is monitored by the movement of the running cage, and sleep / wakefulness is evaluated. If the mice are evaluated after 7 days of stress, the EEG evaluation and the activity evaluation will be similar.

[0048] (Example 5) The method described in Sei H. et al., Life Sci. 2003; 73: 53-59. Male Wistar rats aged 10-12 weeks are reared for 1-7 days with a light-dark cycle of 4 hours dark and 12 hours light, instead of 12 hours dark and 12 hours light. By placing a telemetry thermometer in the abdominal cavity of these animals in advance, it becomes possible to grasp the body temperature rhythm. By changing the light-dark cycle as described above, the modulation of the body temperature rhythm can be detected, and the effect on plasma cortisol concentration and hippocampal BNDF protein amount can also be grasped. [Sequence List Free Text]

[0049] The nucleotide sequence shown in SEQ ID NO:1 is the nucleotide sequence of the HSP70 forward primer. The nucleotide sequence shown in SEQ ID NO:2 is the nucleotide sequence of the HSP70 reverse primer. The nucleotide sequence of SEQ ID NO:3 is the nucleotide sequence of beta 2 microglobulin forward primer. The nucleotide sequence of SEQ ID NO:4 is the nucleotide sequence of beta 2 microglobulin reverse primer.

Claims

1. Formula (I): [Formula 1] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof.

2. The heat shock protein expression inducer according to claim 1 , wherein R is isopropyl, phenyl, or hydroxyphenyl.

3. The heat shock protein expression inducer according to claim 1, wherein R is isopropyl.

4. The heat shock protein expression inducer according to any one of claims 1 to 3, which is in the form of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition.

5. Formula (I): [chemical 2] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof.

6. 6. The sleep-improving agent of claim 5, wherein R is isopropyl, phenyl, or hydroxyphenyl.

7. The sleep-improving agent of claim 5, wherein R is isopropyl.

8. The sleep-improving agent according to any one of claims 5 to 7, which is in the form of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition.

9. Formula (I): [C3] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof.

10. The autonomic nervous regulator according to claim 9, wherein R is isopropyl, phenyl, or hydroxyphenyl.

11. The autonomic nervous regulator according to claim 9, wherein R is isopropyl.

12. The autonomic nervous regulator according to any one of claims 9 to 11, which is in the form of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition.

13. Formula (I): [C4] wherein R is lower alkyl, phenyl, or hydroxyphenyl. or a salt thereof.

14. The anti-stress agent according to claim 13, wherein R is isopropyl, phenyl, or hydroxyphenyl.

15. The anti-stress agent according to claim 13, wherein R is isopropyl.

16. The anti-stress agent according to any one of claims 13 to 15, which is in the form of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition.

Citation Information

Patent Citations

  • Heat shock protein expression inducer

    WO2012043808A1